Search

Your search keyword '"Weisman J"' showing total 338 results
Start Over Author "Weisman J"
338 results on '"Weisman J"'

3. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Author

Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Choon, S, Naldi, L, Lambert, J, Spuls, P, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, Smith, C, Shah, A, Barea, A, Romero-Mate, A, Singapore, A, Paolino, A, Mwale, A, Morales Callaghan, A, Martinez, A, Decrescenzo, A, Pink, A, Jones, A, Sergeant, A, Essex, A, Bewley, A, Makrygeorgou, A, van Huizen, A, Perez-Suarez, B, Farida, B, Clareus, B, Prims, C, Davis, C, Quinlan, C, Maybury, C, Cesar, G, Barclay, C, Greco, C, Brassard, D, Cummings, D, Kolli, D, Descamps, V, Genao, D, Carras, E, Hawryluk, E, Martinez-Garcia, E, Klujszo, E, Dwyer, E, Toni, E, Sonkoly, E, Loayza, E, Dauden, E, Valenzuela, F, Popov, G, King, G, Celine, G, Aparicio, G, Johnston, G, Cardozo, G, Pearson, I, Yanguas, I, Weisman, J, Carolan, J, Hughes, J, Ortiz-Salvador, J, Carrascosa, J, Schwartz, J, Jackson, K, Kerisit, K, Wu, K, Asfour, L, de Graaf, L, Lesort, C, Meuleman, L, Eidsmo, L, Skov, L, Gribben, L, Rustin, M, Velasco, M, Panchal, M, Lakhan, M, Franco, M, Svensson, M, Vandaele, M, Marovt, M, Zargari, O, De Caso, P, Varela, P, Jenkin, P, Phan, C, Hampton, P, Goldsmith, P, Bak, R, Speeckaert, R, Romiti, R, Woolf, R, Mercado-Seda, R, Khatun, R, Ceovic, R, Taberner, R, Cohen, R, Stefanescu, S, Kirk, S, Reeken, S, Ayob, S, Perez-Barrio, S, Piaserico, S, Hoey, S, Torres, T, Talme, T, Desai, T, van Geest, A, King, V, Di Lernia, V, Koreja, Z, Hasab, V, Mahil S. K., Dand N., Mason K. J., Yiu Z. Z. N., Tsakok T., Meynell F., Coker B., McAteer H., Moorhead L., Mackenzie T., Rossi M. T., Rivera R., Mahe E., Carugno A., Magnano M., Rech G., Balogh E. A., Feldman S. R., De La Cruz C., Choon S. E., Naldi L., Lambert J., Spuls P., Jullien D., Bachelez H., McMahon D. E., Freeman E. E., Gisondi P., Puig L., Warren R. B., Di Meglio P., Langan S. M., Capon F., Griffiths C. E. M., Barker J. N., Smith C. H., Shah A., Barea A., Romero-Mate A., Singapore A., Paolino A., Mwale A., Morales Callaghan A. M., Martinez A., DeCrescenzo A., Pink A. E., Jones A., Sergeant A., Essex A., Bewley A., Makrygeorgou A., van Huizen A., Perez-Suarez B., Farida B., Clareus B. W., Prims C. T., Davis C., Quinlan C., Maybury C., Cesar G. A., Barclay C., Greco C., Brassard D., Cummings D., Kolli D., Descamps V., Genao D. R., Carras E., Hawryluk E., Martinez-Garcia E., Klujszo E., Dwyer E., Toni E., Sonkoly E., Loayza E., Dauden E., Valenzuela F., Popov G., King G., Celine G., Aparicio G., Johnston G. A., Cardozo G. A., Pearson I., Yanguas I., Weisman J., Carolan J. E., Hughes J., Ortiz-Salvador J. -M., Carrascosa J. -M., Schwartz J. J., Jackson K., Kerisit K. G., Wu K., Asfour L., de Graaf L., Lesort C., Meuleman L., Eidsmo L., Skov L., Gribben L., Rustin M., Velasco M., Panchal M., Lakhan M., Franco M. D., Svensson M. -L., Vandaele M., Marovt M., Zargari O., De Caso P., Varela P., Jenkin P., Phan C., Hampton P., Goldsmith P., Bak R., Speeckaert R., Romiti R., Woolf R., Mercado-Seda R., Khatun R., Ceovic R., Taberner R., Cohen R. W., Stefanescu S., Kirk S., Reeken S., Ayob S., Perez-Barrio S., Piaserico S., Hoey S., Torres T., Talme T., Desai T. V., van Geest A. J., King V., Di Lernia V., Koreja Z., Hasab V. Z., Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Choon, S, Naldi, L, Lambert, J, Spuls, P, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, Smith, C, Shah, A, Barea, A, Romero-Mate, A, Singapore, A, Paolino, A, Mwale, A, Morales Callaghan, A, Martinez, A, Decrescenzo, A, Pink, A, Jones, A, Sergeant, A, Essex, A, Bewley, A, Makrygeorgou, A, van Huizen, A, Perez-Suarez, B, Farida, B, Clareus, B, Prims, C, Davis, C, Quinlan, C, Maybury, C, Cesar, G, Barclay, C, Greco, C, Brassard, D, Cummings, D, Kolli, D, Descamps, V, Genao, D, Carras, E, Hawryluk, E, Martinez-Garcia, E, Klujszo, E, Dwyer, E, Toni, E, Sonkoly, E, Loayza, E, Dauden, E, Valenzuela, F, Popov, G, King, G, Celine, G, Aparicio, G, Johnston, G, Cardozo, G, Pearson, I, Yanguas, I, Weisman, J, Carolan, J, Hughes, J, Ortiz-Salvador, J, Carrascosa, J, Schwartz, J, Jackson, K, Kerisit, K, Wu, K, Asfour, L, de Graaf, L, Lesort, C, Meuleman, L, Eidsmo, L, Skov, L, Gribben, L, Rustin, M, Velasco, M, Panchal, M, Lakhan, M, Franco, M, Svensson, M, Vandaele, M, Marovt, M, Zargari, O, De Caso, P, Varela, P, Jenkin, P, Phan, C, Hampton, P, Goldsmith, P, Bak, R, Speeckaert, R, Romiti, R, Woolf, R, Mercado-Seda, R, Khatun, R, Ceovic, R, Taberner, R, Cohen, R, Stefanescu, S, Kirk, S, Reeken, S, Ayob, S, Perez-Barrio, S, Piaserico, S, Hoey, S, Torres, T, Talme, T, Desai, T, van Geest, A, King, V, Di Lernia, V, Koreja, Z, Hasab, V, Mahil S. K., Dand N., Mason K. J., Yiu Z. Z. N., Tsakok T., Meynell F., Coker B., McAteer H., Moorhead L., Mackenzie T., Rossi M. T., Rivera R., Mahe E., Carugno A., Magnano M., Rech G., Balogh E. A., Feldman S. R., De La Cruz C., Choon S. E., Naldi L., Lambert J., Spuls P., Jullien D., Bachelez H., McMahon D. E., Freeman E. E., Gisondi P., Puig L., Warren R. B., Di Meglio P., Langan S. M., Capon F., Griffiths C. E. M., Barker J. N., Smith C. H., Shah A., Barea A., Romero-Mate A., Singapore A., Paolino A., Mwale A., Morales Callaghan A. M., Martinez A., DeCrescenzo A., Pink A. E., Jones A., Sergeant A., Essex A., Bewley A., Makrygeorgou A., van Huizen A., Perez-Suarez B., Farida B., Clareus B. W., Prims C. T., Davis C., Quinlan C., Maybury C., Cesar G. A., Barclay C., Greco C., Brassard D., Cummings D., Kolli D., Descamps V., Genao D. R., Carras E., Hawryluk E., Martinez-Garcia E., Klujszo E., Dwyer E., Toni E., Sonkoly E., Loayza E., Dauden E., Valenzuela F., Popov G., King G., Celine G., Aparicio G., Johnston G. A., Cardozo G. A., Pearson I., Yanguas I., Weisman J., Carolan J. E., Hughes J., Ortiz-Salvador J. -M., Carrascosa J. -M., Schwartz J. J., Jackson K., Kerisit K. G., Wu K., Asfour L., de Graaf L., Lesort C., Meuleman L., Eidsmo L., Skov L., Gribben L., Rustin M., Velasco M., Panchal M., Lakhan M., Franco M. D., Svensson M. -L., Vandaele M., Marovt M., Zargari O., De Caso P., Varela P., Jenkin P., Phan C., Hampton P., Goldsmith P., Bak R., Speeckaert R., Romiti R., Woolf R., Mercado-Seda R., Khatun R., Ceovic R., Taberner R., Cohen R. W., Stefanescu S., Kirk S., Reeken S., Ayob S., Perez-Barrio S., Piaserico S., Hoey S., Torres T., Talme T., Desai T. V., van Geest A. J., King V., Di Lernia V., Koreja Z., and Hasab V. Z.

Abstract

Background: The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19), but the data are limited. Objective: Our aim was to characterize the course of COVID-19 in patients with psoriasis and identify factors associated with hospitalization. Methods: Clinicians reported patients with psoriasis with confirmed/suspected COVID-19 via an international registry, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection. Multiple logistic regression was used to assess the association between clinical and/or demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviors. Results: Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% were receiving a nonbiologic, and 10% were not receiving any systemic treatment for psoriasis. In all, 348 patients (93%) were fully recovered from COVID-19, 77 (21%) were hospitalized, and 9 (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted odds ratio [OR] = 1.59 per 10 years; 95% CI = 1.19-2.13), male sex (OR = 2.51; 95% CI = 1.23-5.12), nonwhite ethnicity (OR = 3.15; 95% CI = 1.24-8.03), and comorbid chronic lung disease (OR = 3.87; 95% CI = 1.52-9.83). Hospitalization was more frequent in patients using nonbiologic systemic therapy than in those using biologics (OR = 2.84; 95% CI = 1.31-6.18). No significant differences were found between classes of biologics. Independent patient-reported data (n = 1626 across 48 countries) suggested lower levels of social isolation in individuals receiving nonbiologic systemic therapy than in those receiving biologics (OR = 0.68; 95% CI = 0.50-0.94). Conclusion: In this international case series of patients with moderate-to-severe psoriasis, biologic use was associated with lower risk of COVID-19–related hospitalization than with

Published
2021

5. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)

Author

Blauvelt, A., Guttman-Yassky, E., Paller, A.S., Simpson, E.L., Cork, M.J., Weisman, J., Browning, J., Soong, W., Sun, X., Chen, Z., Kosloski, M.P., Kamal, M.A., Delevry, D., Chuang, C.-C., O’Malley, J.T., and Bansal, A.

Abstract

Background\ud \ud For adolescent patients (aged ≥ 12 to

Published
2022

6. Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.

Author

Ryan, C, Guenther, L, Foley, P, Weisman, J, Burge, RT, Gallo, G, See, K, McKean-Matthews, M, Bertram, CC, Merola, JF, Ryan, C, Guenther, L, Foley, P, Weisman, J, Burge, RT, Gallo, G, See, K, McKean-Matthews, M, Bertram, CC, and Merola, JF

Published
2022

9. Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

Author

Ryan, C., primary, Guenther, L., additional, Foley, P., additional, Weisman, J., additional, Burge, R.T., additional, Gallo, G., additional, See, K., additional, McKean‐Matthews, M., additional, Bertram, C.C., additional, and Merola, J.F., additional

Published
2021
Full Text
View/download PDF

10. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial

Author

Paller, A.S., Siegfried, E.C., Thaçi, D., Wollenberg, A., Cork, M.J., Arkwright, P.D., Gooderham, M., Beck, L.A., Boguniewicz, M., Sher, L., Weisman, J., O’Malley, J.T., Patel, N., Hardin, M., Graham, N.M.H., Ruddy, M., Sun, X., Davis, J.D., Kamal, M.A., Khokhar, F.A., Weinreich, D.M., Yancopoulos, G.D., Beazley, B., Bansal, A., and Shumel, B.

Subjects
fungi
Abstract

Background\ud Children with severe atopic dermatitis (AD) have limited treatment options.\ud \ud Objective\ud We report efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6–11 years with severe AD inadequately controlled with topical therapies.\ud \ud Methods\ud In this double-blind, 16-week, phase 3 trial (NCT03345914), 367 patients were randomized 1:1:1 to 300mg dupilumab every 4 weeks (300mg-q4w), a weight-based regimen of dupilumab every 2 weeks (100mg-q2w, baseline weight

Published
2020

11. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Author

MS Dermatologie/Allergologie, Infection & Immunity, Bieber, T, Thyssen, J P, Reich, K, Simpson, E L, Katoh, N, Torrelo, A, De Bruin-Weller, M, Thaci, D, Bissonnette, R, Gooderham, M, Weisman, J, Nunes, F, Brinker, D, Issa, M, Holzwarth, K, Gamalo, M, Riedl, E, Janes, J, MS Dermatologie/Allergologie, Infection & Immunity, Bieber, T, Thyssen, J P, Reich, K, Simpson, E L, Katoh, N, Torrelo, A, De Bruin-Weller, M, Thaci, D, Bissonnette, R, Gooderham, M, Weisman, J, Nunes, F, Brinker, D, Issa, M, Holzwarth, K, Gamalo, M, Riedl, E, and Janes, J

Published
2021

13. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Author

Bieber, T., primary, Thyssen, J.P., additional, Reich, K., additional, Simpson, E.L., additional, Katoh, N., additional, Torrelo, A., additional, De Bruin‐Weller, M., additional, Thaci, D., additional, Bissonnette, R., additional, Gooderham, M., additional, Weisman, J., additional, Nunes, F., additional, Brinker, D., additional, Issa, M., additional, Holzwarth, K., additional, Gamalo, M., additional, Riedl, E., additional, and Janes, J., additional

Published
2020
Full Text
View/download PDF

17. Persistance de l’amélioration clinique du psoriasis génital après un an de traitement par ixékizumab : résultats d’une étude clinique de phase 3 randomisée contrôlée versus placebo chez des patients atteints de psoriasis génital modéré à sévère (IXORA-Q)

Author

Guenther, L., primary, Potts, A.B., additional, Weisman, J., additional, Poulin, Y., additional, Spelman, L., additional, Burge, R., additional, Erickson, J., additional, Todd, K., additional, Bertram, C.C., additional, Ryan, C., additional, and Rioli, D.-I., additional

Published
2019
Full Text
View/download PDF

18. Constance de la réponse selon les caractéristiques de sévérité de la maladie chez les patients atteints de psoriasis modéré à sévère traités par le guselkumab par rapport au sécukinumab : résultats de l’étude ECLIPSE à la semaine 48

Author

Konstantinou, M.P., primary, Langley, R., additional, Weisman, J., additional, Martorell, A., additional, Fernandez-Penas, P., additional, Hong, C.H., additional, Flavin, S., additional, Hsu, M.C., additional, Randazzo, B., additional, and Armstrong, A., additional

Published
2019
Full Text
View/download PDF

19. 621 Dupilumab in adolescents with moderate-to-severe atopic dermatitis and a history of inadequate response, or intolerance to cyclosporine: subgroup analysis from a pivotal 16-week trial

Author

Paller, A.S., primary, Simpson, E.L., additional, de Bruin-Weller, M., additional, Weisman, J., additional, Lockshin, B., additional, Hultsch, T., additional, Chen, Z., additional, Mina-Osorio, P., additional, Rossi, A.B., additional, Eckert, L., additional, Gadkari, A., additional, and Bansal, A., additional

Published
2019
Full Text
View/download PDF

20. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) (vol 18, pg 273, 2017)

Author

Blauvelt, A, Papp, KA, Griffiths, CEM, Puig, L, Weisman, J, Dutronc, Y, Kerr, LF, Ilo, D, Mallbris, L, and Augustin, M

Abstract

The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt.

Published
2018

21. Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

Author

Ryan, C., Guenther, L., Foley, P., Weisman, J., Burge, R.T., Gallo, G., See, K., McKean‐Matthews, M., Bertram, C.C., and Merola, J.F.

Subjects
CLINICAL trials, QUALITY of life, PATIENTS' attitudes, PSORIASIS, PSORIATIC arthritis, ADULTS
Abstract

Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial 51% of patients in the PBO/IXE group achieved DLQI (0,1) at Week 52, and 94% of patients achieved DLQI item 9 (0,1) at Week 52 (Fig. In the group that received IXE in both periods (IXE/IXE), the proportion of patients with GPSIS-Avoidance (1,2) response persisted through Week 52, with 80% ( I n i = 24/30) achieving GPSIS-Avoidance (1,2). [Extracted from the article]

Published
2022
Full Text
View/download PDF

22. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.

Author

Bieber, T., Thyssen, J.P., Reich, K., Simpson, E.L., Katoh, N., Torrelo, A., De Bruin‐Weller, M., Thaci, D., Bissonnette, R., Gooderham, M., Weisman, J., Nunes, F., Brinker, D., Issa, M., Holzwarth, K., Gamalo, M., Riedl, E., and Janes, J.

Subjects
BARICITINIB, ATOPIC dermatitis, CLINICAL trials, OPPORTUNISTIC infections, HERPES simplex, NOCEBOS
Abstract

Background: Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in late‐stage development for adult patients with moderate‐to‐severe AD. Objective: To report pooled safety data for baricitinib in patients with moderate‐to‐severe AD in the clinical development program including long‐term extension (LTE) studies. Methods: This analysis included patient‐level safety data from six double‐blinded, randomized, placebo‐controlled studies (one phase 2 and five phase 3), one double‐blinded, randomized, LTE study and one open‐label LTE study, reported in three data sets: placebo‐controlled, 2‐mg – 4‐mg extended and All‐bari AD. Safety outcomes include treatment‐emergent adverse events, adverse events of special interest and abnormal laboratory changes. Proportions of patients with events and incidence rates were calculated. Results: Data were collected for 2531 patients who were given baricitinib for 2247 patient‐years (median duration 310 days). The frequency of serious infections, opportunistic infections and conjunctival disorders was low and similar between treatment groups in the placebo‐controlled period. The most common serious infections were eczema herpeticum [n = 11, incidence rates (IR) = 0.5], cellulitis (n = 6, IR = 0.3) and pneumonia (n = 3, IR = 0.1). There were four opportunistic infections (IR = 0.2). No malignancies, gastrointestinal perforations, positively adjudicated cardiovascular events or tuberculosis were reported in the placebo‐controlled period in baricitinib‐treated patients. Frequency of herpes simplex was higher in the 4‐mg group (6.1%) vs. the 2‐mg (3.6%) and placebo group (2.7%); IRs in the extended data set (2‐mg IR = 9.6; 4‐mg IR = 14.5) were lower vs. the placebo‐controlled data set (2‐mg IR = 12.4; 4‐mg IR = 21.3). In the All‐bari AD data set, there were two positively adjudicated major adverse cardiovascular events (2‐mg group): two venous thrombosis events (4‐mg group) and one death. Conclusion: This integrated safety analysis in patients with moderate‐to‐severe AD confirms the established safety profile of baricitinib. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. Acolytes in the Temple of Nike.

Author

Weisman, J.

Subjects
*SPORTS sponsorship, *CORPORATE sponsorship, *OUTDOOR advertising, *BILLBOARDS, *COMMERCIAL art
Abstract

The article focuses on the increasing role of corporate companies in the field of sports in U.S. and around the world. More and more companies have entered in the arena of sports as sponsors and the reflections are spell bounding. Illuminated Coca-Cola signs hang above the four courtside exits. The scorer's table rotates a series of new advertisements every five minutes or so throughout the course of the game, continually catching one's attention with their sudden movements. The scoreboard is a whirl of computer-generated graphics, advertising such products as Isuzu Motors, Miller beer, Oberto Sausage, Elephant Car Wash, Taco Bell, Tombstone Pizza, BP Oil and Ernst Hardware. The phenomenon involves the ever changing facet of sports.

Published
1991

26. Pro Football - The Maiming Game.

Author

Weisman, J.

Subjects
*SUPER Bowl (Football game), *BALL games, *FOOTBALL injuries
Abstract

The article focuses on the Super Bowl. Fortunately, football sells its violence in many ways. Several videos produced by the National Football League (NFL) can help the aficionado fight withdrawal and keep his insanity while awaiting Super Bowl XXVI; these tapes include "The NFL's Greatest Hits," "Thunder and Destruction," and "The NFL's Crunch Course." On November 24, Broderick Thomas, a linebacker with the football team Tampa Bay Buccaneers, felled the New York Giants' Jeff Hostetler, fracturing three of the quarterback's vertebrae and putting him out for the rest of the season. Luckily, he suffered no neurological damage, as did Mike Utley the Sunday before. The rare but dramatic injuries like Utley's obscure the long-range consequences of routine injuries in pro football.

Published
1992

27. The initiation of boiling during pressure transients

Author

Weisman, J, Bussell, G, Jashnani, I. L, and Hsieh, T

Subjects
Thermodynamics And Combustion
Abstract

The initiation of boiling of water on metal surfaces during pressure transients has been investigated. The data were obtained by a new technique in which light beam fluctuations and a pressure signal were simultaneously recorded on a dual beam oscilloscope. The results obtained agreed with those obtained using high speed photography. It was found that, for water temperatures between 90-150 C, the wall superheat required to initiate boiling during a rapid pressure transient was significantly higher than required when the pressure was slowly reduced. This result is explained by assuming that a finite time is necessary for vapor to fill the cavity at which the bubble originates. Experimental measurements of this time are in reasonably good agreement with calculations based on the proposed theory. The theory includes a new procedure for estimating the coefficient of vaporization.

Published
1973

Catalog

Books, media, physical & digital resources
See catalog results